Effect of Vaccinium macrocarpon on MK-801-induced psychosis in mice

被引:4
作者
Shukla, Disha [1 ]
Maheshwari, Rajesh A. [1 ]
Patel, Kirti [2 ]
Balaraman, R. [1 ]
Sen, Ashim Kumar [1 ]
机构
[1] Sumandeep Vidyapeeth, Dept Pharm, Piparia, India
[2] Maharaja Sayajirao Univ Baroda, Fac Pharm, Vadodara, Gujarat, India
关键词
Aqueous cranberry extract; dopamine; gamma-aminobutyric acid; MK-801; psychosis; rota-rod test; RAT MODEL; DOPAMINE; SCHIZOPHRENIA; METABOLITES; DYSFUNCTION; CLOZAPINE; GLUTAMATE; GABA;
D O I
10.4103/ijp.IJP_74_17
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVES: This study was aimed to investigate the effect of aqueous cranberry extract (ACE) on MK-801-induced psychosis in mice. MATERIALS AND METHODS: MK-801-treated mice were administered ACE (1 and 2 g/kg, p.o.) for 14 days. Various behavioral parameters and neurochemical estimations such as dopamine (DA), 5-hydroxytryptamine (5-HT), norepinephrine (NE), gamma-aminobutyric acid (GABA), glutamate, and glycine as well as markers of oxidative stress such as nitrite levels were measured. RESULTS: Psychosis-induced mice showed a significant elevation of immobility time in forted swim test, locomotor activity, and reduction in time of permanency in rota-rod test, escape latency time in Cook's pole test while treatment with ACE showed a significant alteration in above-mentioned behavioral parameters in MK-801-induced psychosis. Moreover, MK-801-induced psychosis in the mice showed a significant increase in DA, 5-HT, and NA levels and decrease in GABA, glutamate, and glycine levels in the brain. In contrast, treatment with ACE at both doses remarkably altered the neurochemical parameters. In addition, ACE-treated mice showed a substantial reduction in acetylcholinesterase, D-amino acid oxidase enzyme activity, and nitrite levels which were elevated by the administration of MK-801. CONCLUSIONS: Treatment with ACE once for 14 days (1 and 2 g/kg) significantly ameliorated the behavioral symptoms in experimentally induced psychosis by virtue of neuromodulation and decreased oxidative stress.
引用
收藏
页码:227 / 235
页数:9
相关论文
共 30 条
[1]  
Andiné P, 1999, J PHARMACOL EXP THER, V290, P1393
[2]  
Andreasen NC, 1990, INT CLIN PSYCHOPHARM, V5, P234
[3]   Evaluation of the Antipsychotic Potential of Panax quinquefolium in Ketamine Induced Experimental Psychosis Model in Mice [J].
Chatterjee, Manavi ;
Singh, Seema ;
Kumari, Reena ;
Verma, Anil Kumar ;
Palit, Gautam .
NEUROCHEMICAL RESEARCH, 2012, 37 (04) :759-770
[4]   Ketamine-enhanced immobility in forced swim test: A possible animal model for the negative symptoms of schizophrenia [J].
Chindo, Ben A. ;
Adzu, Bulus ;
Yahaya, Tijani A. ;
Gamaniel, Karniyus S. .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2012, 38 (02) :310-316
[5]   Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice [J].
Cook, CD ;
Newman, JL ;
Winfree, JC ;
Beardsley, PM .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2004, 77 (02) :309-318
[6]   Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia [J].
Coyle, JT ;
Tsai, G ;
Goff, D .
GLUTAMATE AND DISORDERS OF COGNITION AND MOTIVATION, 2003, 1003 :318-327
[7]   A NEW AND RAPID COLORIMETRIC DETERMINATION OF ACETYLCHOLINESTERASE ACTIVITY [J].
ELLMAN, GL ;
COURTNEY, KD ;
ANDRES, V ;
FEATHERSTONE, RM .
BIOCHEMICAL PHARMACOLOGY, 1961, 7 (02) :88-&
[8]   BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia [J].
Geffen, Yona ;
Nudelman, Abraham ;
Gil-Ad, Irit ;
Rephaeli, Ada ;
Huang, Mei ;
Savitsky, Kinneret ;
Klapper, Leah ;
Ilan, Winkler ;
Meltzer, Herbert Y. ;
Weizman, Abraham .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 (01) :1-13
[9]   Effects of MK-801 on the expression of serine racemase and D-amino acid oxidase mRNAs and on the D-serine levels in rat brain [J].
Hashimoto, Atsushi ;
Yoshikawa, Masanobu ;
Andoh, Hidehiro ;
Yano, Hiroshi ;
Matsumoto, Hideo ;
Kawaguchi, Mitsuru ;
Oka, Tetsuo ;
Kobayashi, Hiroyuki .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 555 (01) :17-22
[10]  
JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301